Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Safety Issues × Clear all

Phase

Phase NA 2 Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 624 Breast Neoplasms 563 Neoplasms 521 Leukemia, Myeloid, Acute 429 Colorectal Neoplasms 401 Multiple Myeloma 400 Melanoma 383 Prostatic Neoplasms 343 Neoplasm Metastasis 325 Pancreatic Neoplasms 319 Lymphoma 309 Recurrence 296 Ovarian Neoplasms 293 Leukemia 268 Lung Neoplasms 261 Lymphoma, Non-Hodgkin 259 Glioblastoma 248 Precursor Cell Lymphoblastic Leukemia-Lymphoma 221 Stomach Neoplasms 219 Leukemia, Lymphocytic, Chronic, B-Cell 208 Carcinoma, Hepatocellular 203 Squamous Cell Carcinoma of Head and Neck 194 Myelodysplastic Syndromes 188 Carcinoma, Renal Cell 188 Lymphoma, Large B-Cell, Diffuse 187 Brain Neoplasms 159 Lymphoma, Follicular 158 Head and Neck Neoplasms 149 Triple Negative Breast Neoplasms 146 Lymphoma, Mantle-Cell 146

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05142592 2025-09-24

Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors

Nanjing Immunophage Biotech Co., Ltd

Phase 1/2 Recruiting

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon ⚡